180 related articles for article (PubMed ID: 30706421)
1. L-Ornithine L-Aspartate (LOLA) for the Treatment of Hepatic Encephalopathy in Cirrhosis: Novel Insights and Translation to the Clinic.
Butterworth RF
Drugs; 2019 Feb; 79(Suppl 1):1-3. PubMed ID: 30706421
[No Abstract] [Full Text] [Related]
2. Beneficial effects of L-ornithine L-aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: a systematic review with meta-analysis.
Butterworth RF
Metab Brain Dis; 2020 Jan; 35(1):75-81. PubMed ID: 31338724
[TBL] [Abstract][Full Text] [Related]
3. [Pathogenesis, diagnosis and treatment of hepatic encephalopathies in patients with liver cirrhosis].
Moĭseienko VO; Manzhaliĭ EH; Solonovych OS; Nykula TD
Lik Sprava; 2014 Nov; (11):39-47. PubMed ID: 25528831
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
Blanco Vela CI; Poo Ramírez JL
Ann Hepatol; 2011 Jun; 10 Suppl 2():S55-9. PubMed ID: 22228883
[TBL] [Abstract][Full Text] [Related]
5. The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition.
Ndraha S; Hasan I; Simadibrata M
Acta Med Indones; 2011 Jan; 43(1):18-22. PubMed ID: 21339541
[TBL] [Abstract][Full Text] [Related]
6. Vigilance and wake EEG architecture in simulated hyperammonaemia: a pilot study on the effects of L-Ornithine-L-Aspartate (LOLA) and caffeine.
Garrido M; Skorucak J; Raduazzo D; Turco M; Spinelli G; Angeli P; Amodio P; Achermann P; Montagnese S
Metab Brain Dis; 2016 Aug; 31(4):965-74. PubMed ID: 27193025
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study.
Poo JL; Góngora J; Sánchez-Avila F; Aguilar-Castillo S; García-Ramos G; Fernández-Zertuche M; Rodríguez-Fragoso L; Uribe M
Ann Hepatol; 2006; 5(4):281-8. PubMed ID: 17151582
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy].
Chen MF; Li RC; Chen CH; Gao XC
Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):718-9, 722. PubMed ID: 15958319
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy.
Kircheis G; Lüth S
Drugs; 2019 Feb; 79(Suppl 1):23-29. PubMed ID: 30706424
[TBL] [Abstract][Full Text] [Related]
10. L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses.
Butterworth RF; McPhail MJW
Drugs; 2019 Feb; 79(Suppl 1):31-37. PubMed ID: 30706425
[TBL] [Abstract][Full Text] [Related]
11. [Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS)].
Hass HG; Nägele T; Seeger U; Hösl F; Gregor M; Kaiser S
Z Gastroenterol; 2005 Apr; 43(4):373-8. PubMed ID: 15830303
[TBL] [Abstract][Full Text] [Related]
12. Possibilities of therapeutic correction of hyperammonemia and minimal hepatic encephalopathy in patients with chronic hepatitis C at the pre-cirrhotic stage.
Buyeverov AO; Bogomolov PO; Mayev IV; Matsievich MV; Uvarova OV
Ter Arkh; 2019 Mar; 91(2):52-58. PubMed ID: 31094172
[TBL] [Abstract][Full Text] [Related]
13. L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy.
Ahmad I; Khan AA; Alam A; Dilshad A; Butt AK; Shafqat F; Malik K; Sarwar S
J Coll Physicians Surg Pak; 2008 Nov; 18(11):684-7. PubMed ID: 18983791
[TBL] [Abstract][Full Text] [Related]
14. [Because hepatic encephalopathy is a frequent contributing factor. Patients with liver cirrhosis are poorer drivers].
MMW Fortschr Med; 2003 Nov; 145(47):61. PubMed ID: 14725039
[No Abstract] [Full Text] [Related]
15. Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials.
He Q; Mao C; Chen Z; Zeng Y; Deng Y; Hu R
Arab J Gastroenterol; 2024 May; 25(2):84-92. PubMed ID: 38403493
[TBL] [Abstract][Full Text] [Related]
16. [Prevention and treatment of hepatic encephalopathy].
Sivolap YP
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503
[TBL] [Abstract][Full Text] [Related]
17. [HEPATIC ENCEPHALOPATHY AND TISSUE ZINC LEVELS IN LIVER DISEASE, DIAGNOSIS AND TREATMENT].
Plotnikova EY; Baranova EN; Maksimov SA
Eksp Klin Gastroenterol; 2015; (7):46-54. PubMed ID: 26817122
[TBL] [Abstract][Full Text] [Related]
18. [Chronic liver diseases. Hepatic encephalopathy too frequently overlooked?].
MMW Fortschr Med; 2000 Jun; 142(25):56-7. PubMed ID: 10920673
[No Abstract] [Full Text] [Related]
19. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: a double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo.
Varakanahalli S; Sharma BC; Srivastava S; Sachdeva S; Dahale AS
Eur J Gastroenterol Hepatol; 2018 Aug; 30(8):951-958. PubMed ID: 29727385
[TBL] [Abstract][Full Text] [Related]
20. A critical analysis of studies assessing L-ornithine-L-aspartate (LOLA) in hepatic encephalopathy treatment.
Soárez PC; Oliveira AC; Padovan J; Parise ER; Ferraz MB
Arq Gastroenterol; 2009; 46(3):241-7. PubMed ID: 19918694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
